as 10-03-2025 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Founded: | 2014 | Country: | United Kingdom |
Employees: | N/A | City: | LONDON |
Market Cap: | 8.6B | IPO Year: | N/A |
Target Price: | $19.94 | AVG Volume (30 days): | 9.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.69 | EPS Growth: | N/A |
52 Week Low/High: | $8.73 - $16.19 | Next Earning Date: | 11-11-2025 |
Revenue: | $23,233,000 | Revenue Growth: | -35.86% |
Revenue Growth (this year): | -14.21% | Revenue Growth (next year): | 248.22% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Venker Eric | ROIV | President & Immunovant CEO | Sep 23 '25 | Sell | $14.83 | 611,000 | $9,061,130.00 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Sep 22 '25 | Sell | $15.00 | 416,182 | $6,240,568.18 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Sep 19 '25 | Sell | $14.95 | 683,818 | $10,223,079.10 | 1,504,959 | |
Gline Matthew | ROIV | CEO | Sep 18 '25 | Buy | $15.07 | 3,315 | $49,957.05 | 17,287,081 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 5 '25 | Sell | $12.96 | 385,816 | $5,000,175.36 | 35,508,359 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 4 '25 | Sell | $12.92 | 194,933 | $2,518,534.36 | 35,508,359 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 3 '25 | Sell | $12.50 | 1,195,000 | $14,937,500.00 | 35,508,359 | |
Venker Eric | ROIV | President & Immunovant CEO | Aug 20 '25 | Sell | $11.72 | 100,000 | $1,172,000.00 | 1,504,959 |
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Simply Wall St.
a day ago
Benzinga
6 days ago
Reuters
13 days ago
Insider Monkey
17 days ago
Zacks
17 days ago
MT Newswires
18 days ago
MT Newswires
18 days ago
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.